(Alliance News) - Nuformix PLC on Wednesday said that Anne Brindley had decided to step down as chief executive officer.
Shares in Nuformix were 14% lower at 1.57 pence each in London on Wednesday.
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing.
Brindley will continue in her current position for the next six months and has committed to assist the company with an orderly transition for that period, Nuformix said. She has been part of the company for eight months since December.
Prior to that, she was CEO of Advent Pharmaceuticals Pty Ltd, a Melbourne-based research and development company focused on generic inhaled products.
"Anne has been made an exceptional offer by another company which she wants to pursue. She is committed to ensuring the progress of the three assets in the Nuformix portfolio over the next six months and will continue to lead this process. In particular, managing the further preclinical work on NXP002 to deliver a more robust data package, the further research on NXP004 and concluding the licensing discussions on NXP001," said Non-Executive Chair Alastair Riddell.
Nuformix will provide further updates to shareholders on the development of the portfolio of assets in the coming months.
By Amrit Sahota; newsroom@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Nuformix (NFX)